+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Duchenne Muscular Dystrophy - Pipeline Review, H1 2019

  • ID: 4760849
  • Drug Pipelines
  • 329 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advanced Medical Projects
  • Biophytis SA
  • Eloxx Pharmaceuticals Inc
  • Galapagos NV
  • NS Pharma Inc
  • Solid Biosciences Inc
  • MORE
Duchenne Muscular Dystrophy - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2019, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Report Highlights

This latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 4, 15, 9, 48 and 21 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 9 and 1 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Advanced Medical Projects
  • Biophytis SA
  • Eloxx Pharmaceuticals Inc
  • Galapagos NV
  • NS Pharma Inc
  • Solid Biosciences Inc
  • MORE
Introduction

Duchenne Muscular Dystrophy - Overview

Duchenne Muscular Dystrophy - Therapeutics Development

Duchenne Muscular Dystrophy - Therapeutics Assessment

Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development

Duchenne Muscular Dystrophy - Drug Profiles

Duchenne Muscular Dystrophy - Dormant Projects

Duchenne Muscular Dystrophy - Discontinued Products

Duchenne Muscular Dystrophy - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Duchenne Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Advanced Medical Projects, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnologies, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Avidity Biosciences LLC, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Beech Tree Labs Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Biogen Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Biophytis SA, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by CRISPR Therapeutics, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Cumberland Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Dystrogen Therapeutics SA, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Editas Medicine Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Eloxx Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Evox Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Fate Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by FibroGen Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Italfarmaco SpA, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Mitobridge Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Mitochon Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by NicOx SA, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Novartis AG, H1 2019

Duchenne Muscular Dystrophy - Pipeline by NS Pharma Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by PeptiDream Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Pfizer Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Progenitor Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Solid Biosciences Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by SOM Biotech SL, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Strykagen Corp, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Summit Therapeutics Plc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Teijin Pharma Ltd, H1 2019

Duchenne Muscular Dystrophy - Pipeline by Tolerion Inc, H1 2019

Duchenne Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd, H1 2019

Duchenne Muscular Dystrophy - Dormant Projects, H1 2019

Duchenne Muscular Dystrophy - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Duchenne Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advanced Medical Projects
  • Akashi Therapeutics Inc
  • Anagenesis Biotechnologies
  • Antisense Therapeutics Ltd
  • Avidity Biosciences LLC
  • Beech Tree Labs Inc
  • Biogen Inc
  • Bioleaders Corp
  • Biophytis SA
  • Capricor Therapeutics Inc
  • Catabasis Pharmaceuticals Inc
  • CRISPR Therapeutics
  • Cumberland Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Dystrogen Therapeutics SA
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • Evox Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • FibroGen Inc
  • Fulcrum Therapeutics Inc
  • Galapagos NV
  • Italfarmaco SpA
  • Milo Biotechnology LLC
  • Mitobridge Inc
  • Mitochon Pharmaceuticals Inc
  • NicOx SA
  • Novartis AG
  • NS Pharma Inc
  • PeptiDream Inc
  • Pfizer Inc
  • Progenitor Therapeutics Ltd
  • PTC Therapeutics Inc
  • ReveraGen BioPharma Inc
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics Inc
  • Solid Biosciences Inc
  • SOM Biotech SL
  • Strykagen Corp
  • Summit Therapeutics Plc
  • Taiho Pharmaceutical Co Ltd
  • Teijin Pharma Ltd
  • Tolerion Inc
  • WAVE Life Sciences Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760849
Adroll
adroll